HRP20090618T1 - Uporaba peptida koji proizlaze iz b beta lanca humanog fibrinogena za liječenje šoka - Google Patents
Uporaba peptida koji proizlaze iz b beta lanca humanog fibrinogena za liječenje šoka Download PDFInfo
- Publication number
- HRP20090618T1 HRP20090618T1 HR20090618T HRP20090618T HRP20090618T1 HR P20090618 T1 HRP20090618 T1 HR P20090618T1 HR 20090618 T HR20090618 T HR 20090618T HR P20090618 T HRP20090618 T HR P20090618T HR P20090618 T1 HRP20090618 T1 HR P20090618T1
- Authority
- HR
- Croatia
- Prior art keywords
- peptide
- sub
- moiety
- shock
- treatment
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract 11
- 230000035939 shock Effects 0.000 title claims abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 102000009123 Fibrin Human genes 0.000 claims abstract 4
- 108010073385 Fibrin Proteins 0.000 claims abstract 4
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims abstract 4
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims abstract 4
- 229950003499 fibrin Drugs 0.000 claims abstract 4
- 102000008790 VE-cadherin Human genes 0.000 claims abstract 3
- 230000004071 biological effect Effects 0.000 claims abstract 3
- 108010018828 cadherin 5 Proteins 0.000 claims abstract 3
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims abstract 3
- 230000001939 inductive effect Effects 0.000 claims abstract 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract 3
- 229920006395 saturated elastomer Polymers 0.000 claims abstract 3
- 229930195734 saturated hydrocarbon Natural products 0.000 claims abstract 3
- 229930195735 unsaturated hydrocarbon Natural products 0.000 claims abstract 3
- 150000001413 amino acids Chemical class 0.000 claims abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 2
- 239000001257 hydrogen Substances 0.000 claims abstract 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims abstract 2
- 210000000056 organ Anatomy 0.000 claims 3
- 208000032456 Hemorrhagic Shock Diseases 0.000 claims 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 2
- 206010049771 Shock haemorrhagic Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 241000712892 Arenaviridae Species 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 231100000699 Bacterial toxin Toxicity 0.000 claims 1
- 206010053567 Coagulopathies Diseases 0.000 claims 1
- 208000001490 Dengue Diseases 0.000 claims 1
- 206010012310 Dengue fever Diseases 0.000 claims 1
- 241000711950 Filoviridae Species 0.000 claims 1
- 241000710831 Flavivirus Species 0.000 claims 1
- 206010022657 Intestinal infarction Diseases 0.000 claims 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 1
- 206010053159 Organ failure Diseases 0.000 claims 1
- 241000150350 Peribunyaviridae Species 0.000 claims 1
- 208000006193 Pulmonary infarction Diseases 0.000 claims 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 claims 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 239000000688 bacterial toxin Substances 0.000 claims 1
- 208000015294 blood coagulation disease Diseases 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 208000025729 dengue disease Diseases 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 230000002008 hemorrhagic effect Effects 0.000 claims 1
- 206010019680 hepatic infarction Diseases 0.000 claims 1
- 150000002430 hydrocarbons Chemical group 0.000 claims 1
- 239000012678 infectious agent Substances 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 201000007970 necrotizing fasciitis Diseases 0.000 claims 1
- 230000007575 pulmonary infarction Effects 0.000 claims 1
- 201000004193 respiratory failure Diseases 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 239000004474 valine Substances 0.000 claims 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 238000007631 vascular surgery Methods 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 abstract 1
- 125000001183 hydrocarbyl group Chemical group 0.000 abstract 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/363—Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT0108704A AT414097B (de) | 2004-06-25 | 2004-06-25 | Pharmazeutische zubereitung zur behandlung von schock |
| AT0004005A AT501263B1 (de) | 2005-01-13 | 2005-01-13 | Pharmazeutische zubereitung zur behandlung von schock |
| PCT/AT2005/000228 WO2006000007A1 (de) | 2004-06-25 | 2005-06-24 | Verwendung von peptiden, die aus der a alpha oder der b beta kette des humanen fibrinogens abgeleitet wurden, zur behandlung von schock |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20090618T1 true HRP20090618T1 (hr) | 2010-01-31 |
Family
ID=35058593
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20090618T HRP20090618T1 (hr) | 2004-06-25 | 2009-11-18 | Uporaba peptida koji proizlaze iz b beta lanca humanog fibrinogena za liječenje šoka |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20080249006A1 (pt) |
| EP (1) | EP1691827B1 (pt) |
| JP (1) | JP2008503503A (pt) |
| AT (1) | ATE439856T1 (pt) |
| AU (1) | AU2005256121B2 (pt) |
| BR (1) | BRPI0506148A (pt) |
| CA (1) | CA2544676A1 (pt) |
| CY (1) | CY1109631T1 (pt) |
| DE (1) | DE502005007926D1 (pt) |
| DK (1) | DK1691827T3 (pt) |
| EA (1) | EA008799B1 (pt) |
| ES (1) | ES2331958T3 (pt) |
| HK (1) | HK1093308A1 (pt) |
| HR (1) | HRP20090618T1 (pt) |
| IL (1) | IL173969A (pt) |
| NZ (1) | NZ545634A (pt) |
| PL (1) | PL1691827T3 (pt) |
| PT (1) | PT1691827E (pt) |
| SI (1) | SI1691827T1 (pt) |
| WO (1) | WO2006000007A1 (pt) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT502987A1 (de) * | 2005-12-23 | 2007-07-15 | Fibrex Medical Res & Dev Gmbh | Pharmazeutische zusammensetzung zur behandlung von hämorrhagischem schock und seinen folgeerscheinungen |
| CA2641909A1 (en) | 2006-02-23 | 2007-08-30 | Fibrex Medical Research & Development Gmbh | Peptides and peptide derivatives, the production thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition |
| US20110098442A1 (en) * | 2006-02-23 | 2011-04-28 | Fibrex Medical Research & Development Gmbh | Peptides and peptide derivatives as well as pharmaceutical compositions containing the same |
| WO2007095659A1 (de) * | 2006-02-23 | 2007-08-30 | Fibrex Medical Research & Development Gmbh | Peptide und peptid-derivate, herstellun derselben sowie deren verwendung zur herstellung eines therapeutisch und/oder präventiv wirkenden arzneimittels |
| WO2009039542A2 (en) * | 2007-09-24 | 2009-04-02 | Fibrex Medical Research & Development Gmbh | Methods of screening for compounds having anti- inflammatory activity and/or prevent / treat vascular leak |
| JP5410997B2 (ja) * | 2008-01-31 | 2014-02-05 | 則行 川村 | うつ病およびうつ状態のマーカーおよびそれを用いた検出・診断 |
| US7884074B2 (en) * | 2008-05-15 | 2011-02-08 | Ikaria Development Subsidiary Two, LLC | Compounds and methods for prevention and/or treatment of inflammation using the same |
| US8088890B2 (en) * | 2008-09-26 | 2012-01-03 | Fibrex Medical Research & Development Gmbh | Peptides and peptidomimetic compounds, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition |
| WO2010043444A2 (en) * | 2008-10-15 | 2010-04-22 | Fibrex Medical Research & Development Gmbh | Pharmaceutical preparation for the treatment and/or prevention of ischemia/reperfusion injury and the sequels thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5965107A (en) * | 1992-03-13 | 1999-10-12 | Diatide, Inc. | Technetium-99m labeled peptides for imaging |
| DE19729591A1 (de) * | 1997-07-10 | 1999-02-11 | Therasorb Medizinische Systeme | Mittel zur Behandlung und/oder Prophylaxe von Mikrozirkulationsstörungen |
| DE50114771D1 (de) * | 2000-12-12 | 2009-04-23 | Fibrex Medical Res & Dev Gmbh | Peptide und/oder Proteine sowie ihre Verwendung zur Herstellung eines therapeutischen und/oder präventiven Arzneimittels |
| AU2002249261A1 (en) * | 2001-03-06 | 2002-09-19 | Axxima Pharmaceuticals Ag | Use of mek inhibitors for treating inflammation and virus induced hemorrhagic shock |
| US20110098442A1 (en) * | 2006-02-23 | 2011-04-28 | Fibrex Medical Research & Development Gmbh | Peptides and peptide derivatives as well as pharmaceutical compositions containing the same |
-
2005
- 2005-06-24 DK DK05752350T patent/DK1691827T3/da active
- 2005-06-24 SI SI200530842T patent/SI1691827T1/sl unknown
- 2005-06-24 CA CA002544676A patent/CA2544676A1/en not_active Abandoned
- 2005-06-24 EA EA200600561A patent/EA008799B1/ru not_active IP Right Cessation
- 2005-06-24 JP JP2007516870A patent/JP2008503503A/ja active Pending
- 2005-06-24 BR BRPI0506148-2A patent/BRPI0506148A/pt not_active IP Right Cessation
- 2005-06-24 EP EP05752350A patent/EP1691827B1/de active Active
- 2005-06-24 NZ NZ545634A patent/NZ545634A/en not_active IP Right Cessation
- 2005-06-24 DE DE502005007926T patent/DE502005007926D1/de active Active
- 2005-06-24 US US10/596,103 patent/US20080249006A1/en not_active Abandoned
- 2005-06-24 WO PCT/AT2005/000228 patent/WO2006000007A1/de not_active Application Discontinuation
- 2005-06-24 ES ES05752350T patent/ES2331958T3/es active Active
- 2005-06-24 PT PT05752350T patent/PT1691827E/pt unknown
- 2005-06-24 AT AT05752350T patent/ATE439856T1/de active
- 2005-06-24 AU AU2005256121A patent/AU2005256121B2/en not_active Ceased
- 2005-06-24 PL PL05752350T patent/PL1691827T3/pl unknown
-
2006
- 2006-02-27 IL IL173969A patent/IL173969A/en not_active IP Right Cessation
- 2006-12-27 HK HK06114161.8A patent/HK1093308A1/xx not_active IP Right Cessation
-
2009
- 2009-11-13 CY CY20091101198T patent/CY1109631T1/el unknown
- 2009-11-18 HR HR20090618T patent/HRP20090618T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2331958T3 (es) | 2010-01-21 |
| EP1691827B1 (de) | 2009-08-19 |
| ATE439856T1 (de) | 2009-09-15 |
| PT1691827E (pt) | 2009-11-23 |
| IL173969A (en) | 2011-06-30 |
| AU2005256121A1 (en) | 2006-04-27 |
| HK1093308A1 (en) | 2007-03-02 |
| EP1691827A1 (de) | 2006-08-23 |
| DK1691827T3 (da) | 2009-12-14 |
| AU2005256121A8 (en) | 2008-08-21 |
| AU2005256121B2 (en) | 2011-03-03 |
| NZ545634A (en) | 2009-09-25 |
| JP2008503503A (ja) | 2008-02-07 |
| US20080249006A1 (en) | 2008-10-09 |
| IL173969A0 (en) | 2006-07-05 |
| BRPI0506148A (pt) | 2006-10-24 |
| EA200600561A1 (ru) | 2006-08-25 |
| CY1109631T1 (el) | 2014-08-13 |
| SI1691827T1 (sl) | 2010-01-29 |
| EA008799B1 (ru) | 2007-08-31 |
| DE502005007926D1 (de) | 2009-10-01 |
| WO2006000007A1 (de) | 2006-01-05 |
| CA2544676A1 (en) | 2006-01-05 |
| PL1691827T3 (pl) | 2010-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20090618T1 (hr) | Uporaba peptida koji proizlaze iz b beta lanca humanog fibrinogena za liječenje šoka | |
| JP5384342B2 (ja) | 癌のような変更された細胞遊走に関連する障害の治療のための薬理学的活性を有するペプチド | |
| JP2018171063A5 (pt) | ||
| RU2012106150A (ru) | Вариантные формы уратоксидазы и их применение | |
| JP4423542B2 (ja) | 抗菌性ポリペプチド及びその利用 | |
| RU2011135755A (ru) | Антибиотические пептиды | |
| AR036196A1 (es) | Agentes de contraste multimericos dirigidos a base de peptidos | |
| JP6553706B2 (ja) | 抗微生物ペプチドデンドリマー | |
| JP2001512739A (ja) | 抗生作用ペプチドから誘導される線状ペプチド、製法および活性物質を仲介する用途 | |
| JP2015534972A5 (pt) | ||
| Jakubke et al. | Peptides from A to Z: a concise encyclopedia | |
| Tsugita et al. | Comparative study of the primary structures of cytochrome b 5 from four species | |
| JPH03503048A (ja) | 心房の，ナトリウム排出亢進性ペプチドの直鎖アナログ | |
| JPH02500517A (ja) | ペプチド化合物 | |
| JP4338516B2 (ja) | 血管新生剤 | |
| MX2022003057A (es) | Nuevos peptidos. | |
| US6713078B2 (en) | Retrocyclins: antiviral and antimicrobial peptides | |
| UA91497C2 (ru) | ПРИМЕНЕНИЕ ПЕПТИДОВ, ВЫДЕЛЕННЫХ ИЗ ЦЕПИ Bb ЧЕЛОВЕЧЕСКОГО ФИБРИНОГЕНА, ДЛЯ ЛЕЧЕНИЯ ШОКА | |
| CA2196053A1 (en) | Two non-contiguous regions contribute to nidogen binding to a single egf-like motif of the laminin .gamma.1 chain | |
| JP2002534996A5 (pt) | ||
| JP7475051B2 (ja) | 新規化合物及びそれを含む血管新生剤 | |
| Henriques et al. | Discovery of peptide drugs from natural sources | |
| DE202015006574U1 (de) | Peptid zur Beschichtung von Oberflächen | |
| Wahyudi et al. | Targeting Disease-Related Proteins via Secondary Protein Structure Formation | |
| BR112020009113A2 (pt) | peptidomiméticos de grampo beta |